 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| 12» |
- ||| lerodalcibep (LIB003) / LIB Therap
P3 data, Journal, Head-to-Head: Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial. (Pubmed Central) - Feb 27, 2025
P3
The LDL cholesterol response was highly variable, but generally similar in patients treated with both lerodalcibep and evolocumab. Importantly, the study showed the inability to predict response based on genotyping, reinforcing the rationale for PCSK9 inhibition in all patients with homozygous familial hypercholesterolemia and continuing its use in responders.
- || Review, Journal: Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American Heart Association Scientific Sessions. (Pubmed Central) - Feb 6, 2025
Included studies assessed effects of intensive blood pressure control in patients with type 2 diabetes (BPROAD); decision support system for physicians to optimize early lipid lowering therapies after acute coronary syndrome (ZODIAC); efficacy and safety of zerlasiran, a short interfering RNA targeting lipoprotein(a) (ALPACAR); efficacy and safety of muvalaplin an oral disrupter of the assembly of lipoprotein(a) particles (KRAKEN); safety and efficacy of obicetrapib in patients with heterozygous familial hypercholesterolemia (BROOKLYN); efficacy and safety of lerodalcibep, a third generation PCSK9 inhibitor in heterozygous familial hypercholesterolemia subjects (LIBerate-HeFH_OLE); personalized app-based coaching to improve physical activity in patients with HFpEF compared to standard care (MyoMobile); semaglutide to improve cardiovascular outcomes in patients with a history of coronary artery bypass surgery and overweight or obesity (the SELECT trial); efficacy and safety of plozasiran in adults with genetically or clinically defined familial chylomicronemia syndrome at high risk of acute pancreatitis (PALISADE); and transcriptomic signatures and predictors of evolocumab added to maximum statin therapy based on intra-coronary plaque characteristics (YELLOW III). Research presented at the 2024 AHA Scientific Sessions emphasized innovative strategies in cardiovascular disease prevention and management.
- |||||| lerodalcibep (LIB003) / LIB Therap
Enrollment open: A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia (clinicaltrials.gov) - Feb 6, 2025
P3, N=210, Recruiting, Sponsor: Hasten Biopharmaceutical Co., Ltd.
Research presented at the 2024 AHA Scientific Sessions emphasized innovative strategies in cardiovascular disease prevention and management. Not yet recruiting --> Recruiting
- || Review, Journal: An up-to-date review of emerging biologic therapies for hypercholesterolemia. (Pubmed Central) - Jan 3, 2025
The antisense oligonucleotide (ASO) and siRNA inhibitors of apoC3 and ANGPTL3 are effective in severe hypertriglyceridemia and homozygous familial hypercholesterolemia, respectively, and may prove to have wider applications. ASO and siRNA inhibitors of Lp(a) are currently in cardiovascular outcome studies.
- | lerodalcibep (LIB003) / LIB Therap
New P3 trial: To evaluate the efficacy and safety of HST101 (Ledaceibup) in Chinese patients with hypercholesterolemia (EUDRACT) - Nov 10, 2024
P3, N=210, Not yet recruiting, Sponsor: Peking University First Hospital; Peking University First Hospital
- ||||| lerodalcibep (LIB003) / LIB Therap
Trial completion: LIBerate-VI: Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD Patients (clinicaltrials.gov) - Oct 23, 2024
P3, N=166, Completed, Sponsor: LIB Therapeutics LLC
ASO and siRNA inhibitors of Lp(a) are currently in cardiovascular outcome studies. Active, not recruiting --> Completed
- |||| lerodalcibep (LIB003) / LIB Therap
Trial completion date, Trial primary completion date: LIBerate-OLE: Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction (clinicaltrials.gov) - Oct 21, 2024
P3, N=2000, Enrolling by invitation, Sponsor: LIB Therapeutics LLC
Active, not recruiting --> Completed Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Oct 2024 --> Jul 2025
- lerodalcibep (LIB003) / LIB Therap
Efficacy and Safety of Lerodalcibep, a Third Generation PCSK9 Inhibitor, in 703 Heterozygous Familial Hypercholesterolemia Subjects in the Open Label Extension Trial (S100A) - Oct 7, 2024 - Abstract #AHA2024AHA_1992;
- lerodalcibep (LIB003) / LIB Therap
Long-term Efficacy of Lerodalcibep in 1,468 Patients at Very High and High Risk for CVD in the 72 week Open-Label Extension Trial (S100A) - Oct 7, 2024 - Abstract #AHA2024AHA_1991;
- |||||||||| lerodalcibep (LIB003) / LIB Therap
New P3 trial: A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia (clinicaltrials.gov) - Aug 22, 2024
P3, N=210, Not yet recruiting, Sponsor: Hasten Biopharmaceutical Co., Ltd.
- || lerodalcibep (LIB003) / LIB Therap
New P1 trial: A Study on Evaluating the Safety of HST101 in Healthy Chinese Participants (clinicaltrials.gov) - Jul 16, 2024
P1, N=30, Not yet recruiting, Sponsor: Hasten Biopharmaceutical Co., Ltd.
- || lerodalcibep (LIB003) / LIB Therap
Clinical, Journal: Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease: A Randomized Clinical Trial. (Pubmed Central) - Jul 3, 2024
P3
These results support long-term use of lerodalcibep in patients with CVD or at high risk of CVD who are unable to achieve adequate LDL-C reduction while receiving maximal tolerated statins alone. ClinicalTrials.gov Identifier: NCT04806893.
- || Review, Journal: Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American College of Cardiology Conference. (Pubmed Central) - Jun 3, 2024
The AEGIS-II randomized patients with type 1 myocardial infarction (MI) with multivessel coronary artery disease and additional CV risk factors and found no benefit in major adverse CV events (MACE) with CSL112, an apolipoprotein A1 infusion shown to increase cholesterol efflux capacity. The Bridge-TIMI 73a trial showed a significant reduction in triglyceride (TG) levels with olezarsen, an antisense mRNA, in patients with moderate hyperTG with elevated CV risk...The VICTORIAN-INITIATE trial showed efficacy and safety in early use of inclisiran in patients with ASCVD who did not reach target LDL-C?<?70
- lerodalcibep (LIB003) / LIB Therap
Randomized, Double-blind, Placebo-controlled, Phase 3, Study To Evaluate Lerodalcibep Long-term Efficacy And Safety In Patients With, Or At Very-high Or High Risk, For Cardiovascular Disease On Stable Lipid-lowering Therapy (Hall B-1 Main Tent) - Mar 25, 2024 - Abstract #ACC2024ACC_8870;
The Bridge-TIMI 73a trial showed a significant reduction in triglyceride (TG) levels with olezarsen, an antisense mRNA, in patients with moderate hyperTG with elevated CV risk...The VICTORIAN-INITIATE trial showed efficacy and safety in early use of inclisiran in patients with ASCVD who did not reach target LDL-C?<?70 There is no abstract associated with this presentation.
- lerodalcibep (LIB003) / LIB Therap
Randomized, Double-blind, Placebo-controlled, Phase 3, Study To Evaluate Lerodalcibep Long-term Efficacy And Safety In Patients With, Or At Very-high Or High Risk, For Cardiovascular Disease On Stable Lipid-lowering Therapy (Hall B-1 Main Tent) - Feb 5, 2024 - Abstract #ACC2024ACC_8191;
There is no abstract associated with this presentation. Abstract is embargoed at this time.
- | Journal: PCSK9-directed therapies: an update. (Pubmed Central) - Jan 26, 2024
Long-term inhibition of PCSK9 with monoclonal antibodies is safe and conveys sustained cardiovascular benefit. Novel strategies to inhibit PCSK9 function such as orally available drugs, RNA targeting, and one-time treatment with gene editing may further enhance the therapeutic armamentarium and enable novel preventive strategies.
- lerodalcibep (LIB003) / LIB Therap
LONG-TERM EFFICACY AND SAFETY OF LERODALCIBEP IN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (Moderated Poster Theater 08) - Jan 26, 2024 - Abstract #ACC2024ACC_3985;
Overall mean age (range) was 52.8 (18-79) years, 51.3% female, 86% white and 14% South Asian, multiracial or black, with 88% on statins, 50.6% on ezetimibe and mean (SD) LDL-C of 153.4 (67.0) mg/dL. Lerodalcibep dosed monthly significantly and persistently reduced LDL-C, apo-B and Lp(a) in HeFH subjects with no attenuation and with a safety profile similar to placebo.
- || Review, Journal: Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 European Society of Cardiology Congress. (Pubmed Central) - Jan 8, 2024
The late-breaking clinical science at the 2023 congress of the ESC extends the known safety and efficacy data of a PCSK9i with the introduction of new drugs in this class. Using cumulative exposure to LDL-C rather than a single value will help clinicians tailor the LDL-C reduction strategy to individual risk and is an important step towards personalized medicine.
- ||||||| lerodalcibep (LIB003) / LIB Therap
Trial completion, Trial completion date, Trial primary completion date: LIBerate-FH: Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction (clinicaltrials.gov) - Dec 10, 2023
P3, N=478, Completed, Sponsor: LIB Therapeutics LLC
Using cumulative exposure to LDL-C rather than a single value will help clinicians tailor the LDL-C reduction strategy to individual risk and is an important step towards personalized medicine. Active, not recruiting --> Completed | Trial completion date: May 2023 --> Dec 2023 | Trial primary completion date: Apr 2023 --> Jul 2023
- |||| lerodalcibep (LIB003) / LIB Therap
Enrollment closed, Trial completion date, Trial primary completion date: LIBerate-VI: Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD Patients (clinicaltrials.gov) - Dec 10, 2023
P3, N=160, Active, not recruiting, Sponsor: LIB Therapeutics LLC
Active, not recruiting --> Completed | Trial completion date: May 2023 --> Dec 2023 | Trial primary completion date: Apr 2023 --> Jul 2023 Enrolling by invitation --> Active, not recruiting | Trial completion date: Dec 2023 --> Jul 2024 | Trial primary completion date: Oct 2023 --> May 2024
- | lerodalcibep (LIB003) / LIB Therap
Journal: Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial. (Pubmed Central) - Aug 28, 2023
Enrolling by invitation --> Active, not recruiting | Trial completion date: Dec 2023 --> Jul 2024 | Trial primary completion date: Oct 2023 --> May 2024 Lerodalcibep, a novel anti-PCSK9 small binding protein dosed monthly as an alternative to monoclonal antibodies, significantly reduced LDL-C in subjects with HeFH with a safety profile similar to placebo.
- |||| lerodalcibep (LIB003) / LIB Therap
Trial completion date, Trial primary completion date: LIBerate-OLE: Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction (clinicaltrials.gov) - Mar 29, 2023
P3, N=2000, Enrolling by invitation, Sponsor: LIB Therapeutics LLC
Lerodalcibep, a novel anti-PCSK9 small binding protein dosed monthly as an alternative to monoclonal antibodies, significantly reduced LDL-C in subjects with HeFH with a safety profile similar to placebo. Trial completion date: Mar 2024 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Oct 2024
- ||||||| lerodalcibep (LIB003) / LIB Therap
Trial completion: LIBerate-H2H: Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients (clinicaltrials.gov) - Mar 29, 2023
P3, N=204, Completed, Sponsor: LIB Therapeutics LLC
Trial completion date: Mar 2024 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Oct 2024 Active, not recruiting --> Completed
- ||||| lerodalcibep (LIB003) / LIB Therap
Trial completion, Trial completion date: Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH (clinicaltrials.gov) - Mar 29, 2023
P3, N=65, Completed, Sponsor: LIB Therapeutics LLC
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Sep 2022 --> Jan 2023
- ||||| lerodalcibep (LIB003) / LIB Therap
Enrollment closed: LIBerate-HR: Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C Reduction (clinicaltrials.gov) - Nov 4, 2022
P3, N=900, Active, not recruiting, Sponsor: LIB Therapeutics LLC
Active, not recruiting --> Completed | Trial completion date: Sep 2022 --> Jan 2023 Enrolling by invitation --> Active, not recruiting
- ||||| lerodalcibep (LIB003) / LIB Therap
Enrollment closed: LIBerate-FH: Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction (clinicaltrials.gov) - Nov 4, 2022
P3, N=450, Active, not recruiting, Sponsor: LIB Therapeutics LLC
Enrolling by invitation --> Active, not recruiting Enrolling by invitation --> Active, not recruiting
- ||||| lerodalcibep (LIB003) / LIB Therap
Enrollment closed: LIBerate-CVD: Study of Efficacy and Safety of LIB003 in Patient With CVD on Statins Requiring Additional LDL-C Reduction (clinicaltrials.gov) - Nov 4, 2022
P3, N=900, Active, not recruiting, Sponsor: LIB Therapeutics LLC
Enrolling by invitation --> Active, not recruiting Enrolling by invitation --> Active, not recruiting
- |||| lerodalcibep (LIB003) / LIB Therap
Enrollment open, Trial completion date, Trial primary completion date: LIBerate-VI: Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD Patients (clinicaltrials.gov) - Jul 15, 2022
P3, N=160, Enrolling by invitation, Sponsor: LIB Therapeutics LLC
Enrolling by invitation --> Active, not recruiting Not yet recruiting --> Enrolling by invitation | Trial completion date: Jul 2023 --> Oct 2023 | Trial primary completion date: Jun 2023 --> Sep 2023
- |||| lerodalcibep (LIB003) / LIB Therap
Trial completion date, Trial primary completion date: LIBerate-HR: Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C Reduction (clinicaltrials.gov) - Jul 14, 2022
P3, N=900, Enrolling by invitation, Sponsor: LIB Therapeutics LLC
Not yet recruiting --> Enrolling by invitation | Trial completion date: Jul 2023 --> Oct 2023 | Trial primary completion date: Jun 2023 --> Sep 2023 Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Oct 2022 --> Oct 2023
- |||| lerodalcibep (LIB003) / LIB Therap
Trial completion date, Trial primary completion date: LIBerate-FH: Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction (clinicaltrials.gov) - Jul 14, 2022
P3, N=600, Enrolling by invitation, Sponsor: LIB Therapeutics LLC
Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Oct 2022 --> Oct 2023 Trial completion date: May 2022 --> May 2023 | Trial primary completion date: Feb 2022 --> Mar 2023
- |||| lerodalcibep (LIB003) / LIB Therap
Trial completion date, Trial primary completion date: LIBerate-CVD: Study of Efficacy and Safety of LIB003 in Patient With CVD on Statins Requiring Additional LDL-C Reduction (clinicaltrials.gov) - Jul 14, 2022
P3, N=900, Enrolling by invitation, Sponsor: LIB Therapeutics LLC
Trial completion date: May 2022 --> May 2023 | Trial primary completion date: Feb 2022 --> Mar 2023 Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Oct 2022 --> Oct 2023
- ||||| lerodalcibep (LIB003) / LIB Therap
Enrollment closed: LIBerate-H2H: Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients (clinicaltrials.gov) - Jul 14, 2022
P3, N=204, Active, not recruiting, Sponsor: LIB Therapeutics LLC
Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Oct 2022 --> Oct 2023 Enrolling by invitation --> Active, not recruiting
- || lerodalcibep (LIB003) / LIB Therap
Trial completion: Cross-Over Study to Compare the Pharmacokinetics and Pharmacodynamics of LIB003 Process 1 and Process 2 Drug Product (clinicaltrials.gov) - Jul 14, 2022
P3, N=22, Completed, Sponsor: LIB Therapeutics LLC
Enrolling by invitation --> Active, not recruiting Active, not recruiting --> Completed
- || lerodalcibep (LIB003) / LIB Therap
Enrollment closed: Cross-Over Study to Compare the Pharmacokinetics and Pharmacodynamics of LIB003 Process 1 and Process 2 Drug Product (clinicaltrials.gov) - Mar 8, 2022
P3, N=20, Active, not recruiting, Sponsor: LIB Therapeutics LLC
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| lerodalcibep (LIB003) / LIB Therap
New P3 trial: Cross-Over Study to Compare the Pharmacokinetics and Pharmacodynamics of LIB003 Process 1 and Process 2 Drug Product (clinicaltrials.gov) - Feb 9, 2022
P3, N=20, Recruiting, Sponsor: LIB Therapeutics LLC
- |||| lerodalcibep (LIB003) / LIB Therap
Trial completion date, Trial primary completion date: LIBerate-H2H: Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients (clinicaltrials.gov) - Feb 9, 2022
P3, N=220, Enrolling by invitation, Sponsor: LIB Therapeutics LLC
Recruiting --> Active, not recruiting Trial completion date: Oct 2021 --> Oct 2022 | Trial primary completion date: Sep 2021 --> Sep 2022
- |||| lerodalcibep (LIB003) / LIB Therap
Trial completion date, Trial initiation date, Trial primary completion date: LIBerate-VI: Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD Patients (clinicaltrials.gov) - Feb 9, 2022
P3, N=160, Not yet recruiting, Sponsor: LIB Therapeutics LLC
Trial completion date: Oct 2021 --> Oct 2022 | Trial primary completion date: Sep 2021 --> Sep 2022 Trial completion date: Dec 2022 --> Jul 2023 | Initiation date: Oct 2021 --> Mar 2022 | Trial primary completion date: Oct 2022 --> Jun 2023
- |||| lerodalcibep (LIB003) / LIB Therap
Enrollment closed: Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH (clinicaltrials.gov) - Aug 12, 2021
P3, N=70, Active, not recruiting, Sponsor: LIB Therapeutics LLC
Trial completion date: Dec 2022 --> Jul 2023 | Initiation date: Oct 2021 --> Mar 2022 | Trial primary completion date: Oct 2022 --> Jun 2023 Enrolling by invitation --> Active, not recruiting
- |||||||| lerodalcibep (LIB003) / LIB Therap
New P3 trial: LIBerate-VI: Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD Patients (clinicaltrials.gov) - Aug 12, 2021
P3, N=160, Not yet recruiting, Sponsor: LIB Therapeutics LLC
- |||||| lerodalcibep (LIB003) / LIB Therap
Enrollment open: LIBerate-HR: Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C Reduction (clinicaltrials.gov) - Apr 23, 2021
P3, N=900, Enrolling by invitation, Sponsor: LIB Therapeutics LLC
Enrolling by invitation --> Active, not recruiting Not yet recruiting --> Enrolling by invitation
- |||||| lerodalcibep (LIB003) / LIB Therap
Enrollment open: LIBerate-FH: Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction (clinicaltrials.gov) - Apr 23, 2021
P3, N=600, Enrolling by invitation, Sponsor: LIB Therapeutics LLC
Not yet recruiting --> Enrolling by invitation Not yet recruiting --> Enrolling by invitation
- |||||| lerodalcibep (LIB003) / LIB Therap
Enrollment open: LIBerate-CVD: Study of Efficacy and Safety of LIB003 in Patient With CVD on Statins Requiring Additional LDL-C Reduction (clinicaltrials.gov) - Apr 23, 2021
P3, N=900, Enrolling by invitation, Sponsor: LIB Therapeutics LLC
Not yet recruiting --> Enrolling by invitation Not yet recruiting --> Enrolling by invitation
- |||||| lerodalcibep (LIB003) / LIB Therap
Enrollment open: LIBerate-H2H: Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients (clinicaltrials.gov) - Apr 23, 2021
P3, N=220, Enrolling by invitation, Sponsor: LIB Therapeutics LLC
Not yet recruiting --> Enrolling by invitation Not yet recruiting --> Enrolling by invitation
- |||||||||| lerodalcibep (LIB003) / LIB Therap
New P3 trial: LIBerate-HR: Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C Reduction (clinicaltrials.gov) - Mar 19, 2021
P3, N=900, Not yet recruiting, Sponsor: LIB Therapeutics LLC
- |||||||||| lerodalcibep (LIB003) / LIB Therap
New P3 trial: LIBerate-FH: Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction (clinicaltrials.gov) - Mar 15, 2021
P3, N=600, Not yet recruiting, Sponsor: LIB Therapeutics LLC
- |||||||||| lerodalcibep (LIB003) / LIB Therap
New P3 trial: LIBerate-CVD: Study of Efficacy and Safety of LIB003 in Patient With CVD on Statins Requiring Additional LDL-C Reduction (clinicaltrials.gov) - Mar 15, 2021
P3, N=900, Not yet recruiting, Sponsor: LIB Therapeutics LLC
- |||||||||| lerodalcibep (LIB003) / LIB Therap
New P3 trial: LIBerate-OLE: Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction (clinicaltrials.gov) - Mar 15, 2021
P3, N=2000, Enrolling by invitation, Sponsor: LIB Therapeutics LLC
- |||||||||| lerodalcibep (LIB003) / LIB Therap
New P3 trial: LIBerate-H2H: Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients (clinicaltrials.gov) - Mar 9, 2021
P3, N=220, Not yet recruiting, Sponsor: LIB Therapeutics LLC
- ||| lerodalcibep (LIB003) / LIB Therap
Trial completion date, Trial primary completion date: Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH (clinicaltrials.gov) - Mar 3, 2021
P3, N=70, Enrolling by invitation, Sponsor: LIB Therapeutics LLC
Not yet recruiting --> Enrolling by invitation Trial completion date: Jun 2021 --> Jun 2022 | Trial primary completion date: Mar 2021 --> May 2022
- || lerodalcibep (LIB003) / LIB Therap
Trial completion, Trial completion date: Open-Label Extension to Evaluate the Longer Term Efficacy and Safety of LIB003 (clinicaltrials.gov) - Nov 3, 2020
P2b, N=32, Completed, Sponsor: LIB Therapeutics LLC
Trial completion date: Jun 2021 --> Jun 2022 | Trial primary completion date: Mar 2021 --> May 2022 Active, not recruiting --> Completed | Trial completion date: May 2020 --> Aug 2020